From Seoul: AIGEN Sciences is using generative AI for drug discovery and development - in addition to already having 16 programs, the company earlier this year struck an ADC deal with Hanmi

Nov 21, 2024
1 min read

CEO Jaewoo Kang, a computer scientist, describes AIGEN's computational heavy platform. Plus, he discusses three of the most advanced programs: a pan-KRAS inhibitor, USP1, and developing linkers and payloads to help Hanmi with ADCs.

https://vimeo.com/1031943046

Recent Posts

See All

$BIO 2026: The gout market is currently served by two extremes, generic allopurinol in first line and a therapy for extreme refractory cases. Crystalys' experienced team wants to change that$

BIO 2026: The gout market is currently served by two extremes, generic allopurinol in first line and a therapy for extreme refractory cases. Crystalys' experienced team wants to change that

BIO 2026: Rakuten Medical's drug-device 'photoimmunotherapy' is already approved in Japan for head & neck cancer - it is currently in a global phase 3 with an eye on a U.S. approval

BIO 2026: After presenting updated data at both ASH and EHA, Paris based Enterome is hoping to start a phase 3 for its multi-target peptide immunotherapy in follicular lymphoma

From Seoul: AIGEN Sciences is using generative AI for drug discovery and development - in addition to already having 16 programs, the company earlier this year struck an ADC deal with Hanmi

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight